Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1b)

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1032-1037

  Ketterer, N ^a   Coiffier, B ^b   Thieblemont, C ^c   Ferme C ^d   Briere J ^c   Casasnovas, O ^e   Bologna, S ^f   Christian, B ^g   Connerotte, T ^h   Reher C ⁱ   Bordessoule, D ^j   Fruchart, C ^k   Delarue, R ^l   Bonnet, C ^m   Morschhauser, F ⁿ   Anglaret, B ^o   Soussain, C ^p   Fabiani, B ^q   Tilly, H ^r   Haioun, C ^s  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f CHU NANCY BRABOIS   (France)

^g Bon Secours Hospital   (France)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j LIMOGES UNIVERSITY HOSPITAL   (France)

^k Centre Franois Baclesse   (France)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

^m UNIVERSITY OF LIÈGE   (Belgium)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o Department of Hematology   (France)

^p Rene Huguenin Hospital   (France)

^q HÔPITAL SAINT ANTOINE   (France)

^r CENTRE HENRI BECQUEREL   (France)

^s HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

Chemotherapy; Localized lymphoma; Low risk; Rituximab; Treatment

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINDESINE;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG INFUSION; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INFECTION; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; VASCULAR DISEASE;

EID: 84875626098     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds600     Document Type: Article

References (18)

1. Sweet DL, Kinzie J, Gaeke ME et al.. Survival of patients with localized diffuse histiocytic lymphoma. Blood 1981; 58: 1218-1223.
2. Connors JM, Klimo P, Fairey RN et al.. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 1987; 107: 25-30.
3. Cabanillas F, Bodey GP, Freireich EJ. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 1980; 46: 2356-2359.
4. Miller TP, Dahlberg S, Cassady JR et al.. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21-26.
5. Reyes F, Lepage E, Ganem G et al.. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197-1205.
6. Coiffier B, Lepage E, Briere J et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
7. Pfreundschuh M, Trümper L, Osterborg A et al.. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
8. Swerdlow SH, Campo E, Harris NL et al.. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2008.
9. The International Non-Hodgkins Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkins lymphoma. N Engl J Med 1993; 329: 987-994.
10. Cheson BD, Horning SJ, Coiffier B et al.. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
11. Miller TP, Leblanc M, Spier PM et al.. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkins lymphoma: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001; 98(Suppl.): S742-S743.
12. Horning SJ, Weller E, Kim K et al.. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkins lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004; 22: 3032-3038.
13. Bonnet C, Fillet G, Mounier N et al.. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 787-792.
14. Persky DO, Unger JM, Spier CM et al.. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008; 26: 2258-2263.
15. Dunleavy K, Pittaluga S, Janik J et al.. Primary mediastinal large B-cell lymphoma (PMBL) outcome is significantly improved by the addition of rituximab to dose adjusted (DA)-EPOCH and overcomes the need for radiation. Blood 2005; 106(Suppl.): 929a.
16. Sehn LH, Berry B, Chhanabhai M et al.. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861.
17. Recher C, Coiffier B, Haioun C et al.. A prospective randomized study comparing dose intensive immuno-chemotherapy with R-ACVBP versus standard R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL). Groupe d'Etude des Lymphomes de l'Adulte (GELA) Study LNH03-2B. Lancet 2011; 378: 1858-1867.
18. Pfreundschuh M, Zeynalova S, Poeschel V et al.. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dosedense rituximab: results of the Dense-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). J Clin Oncol 2008; 26: 8508a.